{"id":"W4289878834","doi":"10.1093/noajnl/vdac078.029","title":"CLRM-09 FIRST-LINE Tumor TREATING FIELDS (200 KHZ) THERAPY FOR NEWLY-DIAGNOSED GLIOBLASTOMA: THE PHASE 3 TRIDENT TRIAL (EF-32)","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Temozolomide; Medicine; Internal medicine; Oncology; Clinical endpoint; Progression-free survival; Phases of clinical research; Radiation therapy; Clinical trial; Adverse effect; Cancer; Chemotherapy; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004112858,0.0003634796,0.0007477144,0.0001659939,0.0009689661,0.00003140296,0.0002950305,0.00009359916,0.0006563688],"category_scores_gemma":[0.0007196128,0.0002482558,0.0003868176,0.0003947358,0.0001414266,0.0001239927,0.0001045714,0.0004532261,0.00001450447],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002374938,"about_ca_system_score_gemma":0.0002728912,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004873161,"about_ca_topic_score_gemma":0.0002722391,"domain_scores_codex":[0.9974545,0.000289378,0.0006400576,0.0006513004,0.0003919454,0.000572791],"domain_scores_gemma":[0.994682,0.004153519,0.0004000998,0.0004964833,0.0001024758,0.0001654824],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.3022997,0.02292669,0.006100172,0.0001089528,0.0006842862,0.005222927,0.002297698,0.004512238,0.007659799,0.0004126214,0.04248835,0.6052866],"study_design_scores_gemma":[0.2495317,0.0527859,0.0002699616,0.00002064923,0.000310667,0.0003570539,0.000729098,0.0005452312,0.01299705,0.0003888246,0.6818054,0.0002584776],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9700257,0.00544108,0.00009116151,0.01709188,0.00233429,0.004350699,0.0001143984,0.0001393349,0.0004114765],"genre_scores_gemma":[0.9854834,0.001693112,0.0003267017,0.005993219,0.001293247,0.004952187,0.00006404577,0.00005859042,0.0001355159],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.639317,"threshold_uncertainty_score":0.999997,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02669825263285219,"score_gpt":0.3462762793236294,"score_spread":0.3195780266907772,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}